|Bid||3.78 x 5000|
|Ask||5.29 x 100|
|Day's range||4.09 - 4.29|
|52-week range||2.30 - 7.24|
|PE ratio (TTM)||N/A|
|Earnings date||9 May 2018 - 14 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.25|
The Irvine, California-based company said it had a loss of 17 cents per share. The natural products company posted revenue of $7.5 million in the period. For the year, the company reported that its loss ...
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today it will sponsor a gathering of scientific leaders at the 2018 NAD+ Summit on January 26-28, 2018 in San Diego, CA. In collaboration with the Center for Research on Addiction and Brain Health, the NAD+ Treatment Center, and Springfield Wellness Center, ChromaDex will share its knowledge of nicotinamide riboside (NR) and nicotinamide adenine dinucleotide (NAD+) with leading scientists, doctors, innovators and thought leaders in the NAD+ community along with all other consumers and participants who are welcome to attend the summit. ChromaDex has enabled the proliferation of NR research by developing, commercializing and supplying NIAGEN®, which has been rigorously tested for safety and has been the subject of Notifications filed with the U.S. Food and Drug Administration (FDA).
The Irvine, California-based company said it had profit of 4 cents per share. Losses, adjusted to account for discontinued operations, were 7 cents per share. The natural products company posted revenue ...